Ironwood, Allergan score data backing for smaller Linzess dose; Lupin signs up to market BI diabetes med in India;

> Ironwood Pharmaceuticals ($IRWD) said a smaller dose of the constipation drug Linzess was effective in a late-stage study; the company and partner Allergan ($AGN) plan to ask the FDA to approve the 72-mcg dose early next year. Report

> India's Lupin inked a deal to co-market Boehringer Ingelheim's diabetes drug Trajenta in its home country, under a different brand name, Ondero. Report

> Bristol-Myers Squibb's ($BMY) Ready. Raise. Rise. campaign recognized 23 cancer advocacy groups in an immuno-oncology awareness effort. Release

> GlaxoSmithKline ($GSK) is socking £1.3 million into a marketing push for a new toothpaste product, Sensodyne True White; the move follows an overall simplification of the Sensodyne product line. Report

> Pfizer ($PFE) snapped up full rights to the Gaucher's disease drug Elelyso from partner Protalix for $36 million cash, in a deal that also includes a $10 million investment in the smaller company. Report

And Finally... Pfizer's stop-smoking drug Chantix, equally effective in men and women after one year, was more helpful to women than men early on in therapy, according to a new study. Report

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

Gilead is working to move CAR-T med Yescarta into other types of NHL, and if data from an interim trial look-in are any indication, it's on its way.